Oxygenta Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹33 crore and a net loss of ₹2.74 crore for the September 2026 quarter.
Oxygenta Pharma (BSE: OXYGENTAPH) closed at ₹50.00 on 20 Nov 2026, down 15.4% over the past year. Its market capitalisation is ₹185 crore.
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.